Ironwood Pharmaceuticals Share Price (NASDAQ: IRWD)

$1.32

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Ironwood Pharmaceuticals Stock chart to analyse performance

Ironwood Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$1.30
Today's High:$1.33
$1.32
1.52%
Downside
Day's Volatility :2.26%
Upside
0.75%
52 Weeks Low:$0.53
52 Weeks High:$5.19
$1.32
60.07%
Downside
52 Weeks Volatility :89.84%
Upside
74.57%

Ironwood Pharmaceuticals Stock Returns

Period	Ironwood Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	113.02%	3.6%	0.0%
6 Months	-12.83%	-7.7%	0.0%
1 Year	-73.39%	-12.6%	0.0%
3 Years	-87.77%	9.5%	-4.7%

Ironwood Pharmaceuticals, Inc. Key Stats

Check Ironwood Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.32
Open	$1.32
Today's High	$1.33
Today's Low	$1.3
Market Capitalization	$214.4M
Today's Volume	$548.1K
52 Week High	$5.19
52 Week Low	$0.5271
Revenue TTM	$308.5M
EBITDA	$93.7M
Earnings Per Share (EPS)	$-0.05
Profit Margin	-2.56%
Quarterly Earnings Growth YOY	-0.77%
Return On Equity TTM	-574.72%

Stock Returns calculator for Ironwood Pharmaceuticals Stock including INR - Dollar returns

The Ironwood Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Ironwood Pharmaceuticals investment value today

Current value as on today

₹31,371

Returns

₹68,629

(-68.63%)

Returns from Ironwood Pharmaceuticals Stock

₹73,913 (-73.91%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Ironwood Pharmaceuticals Stock

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Ironwood Pharmaceuticals Stock from India on INDmoney has increased by 2% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ironwood Pharmaceuticals, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
9.97%
Armistice Capital, LLC
9.94%
Sarissa Capital Management LP
9.80%
BlackRock Inc
7.31%
Renaissance Technologies Corp
6.12%
Millennium Management LLC
3.92%

Analyst Recommendation on Ironwood Pharmaceuticals Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Ironwood Pharmaceuticals(by analysts ranked 0 to 5 stars)

Ironwood Pharmaceuticals Share Price Target

What analysts predicted

Downside of 28.03%

Target:

$0.95

Current:

$1.32

Ironwood Pharmaceuticals share price target is $0.95, a slight Downside of 28.03% compared to current price of $1.32 as per analysts' prediction.

Ironwood Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, IRWD stock has moved up by 59.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 41.14M → 85.23M (in $), with an average increase of 51.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -37.38M → 23.59M (in $), with an average increase of 258.4% per quarter
IRWD vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 83.7%
IRWD vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 35.1% return, outperforming this stock by 122.9%
Price to Sales
ForIRWD every $1 of sales, investors are willing to pay $0.7, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Ironwood Pharmaceuticals, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$428.4M	↑ 23.59%
Net Income	$21.5M	↓ 107.62%
Net Profit Margin	5.02%	↑ 86.48%

	FY20	Y/Y Change
Revenue	$389.5M	↓ 9.08%
Net Income	$106.2M	↑ 393.73%
Net Profit Margin	27.26%	↑ 22.24%

	FY21	Y/Y Change
Revenue	$413.8M	↑ 6.22%
Net Income	$528.4M	↑ 397.71%
Net Profit Margin	127.72%	↑ 100.46%

	FY22	Y/Y Change
Revenue	$410.6M	↓ 0.76%
Net Income	$175.1M	↓ 66.87%
Net Profit Margin	42.64%	↓ 85.08%

	FY23	Y/Y Change
Revenue	$442.7M	↑ 7.83%
Net Income	$-1.0B	↓ 672.5%
Net Profit Margin	-226.37%	↓ 269.01%

	FY24	Y/Y Change
Revenue	$351.4M	↓ 20.63%
Net Income	$880.0K	↓ 100.09%
Net Profit Margin	0.25%	↑ 226.62%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$74.9M	↓ 36.3%
Net Income	$-4.2M	↑ 282.89%
Net Profit Margin	-5.56%	↓ 4.64%

	Q2 FY24	Q/Q Change
Revenue	$94.4M	↑ 26.07%
Net Income	$-860.0K	↓ 79.34%
Net Profit Margin	-0.91%	↑ 4.65%

	Q3 FY24	Q/Q Change
Revenue	$91.6M	↓ 2.97%
Net Income	$3.6M	↓ 523.95%
Net Profit Margin	3.98%	↑ 4.89%

	Q4 FY24	Q/Q Change
Revenue	$90.5M	↓ 1.14%
Net Income	$2.3M	↓ 38.12%
Net Profit Margin	2.49%	↓ 1.49%

	Q1 FY25	Q/Q Change
Revenue	$41.1M	↓ 54.56%
Net Income	$-37.4M	↓ 1757.18%
Net Profit Margin	-90.87%	↓ 93.36%

	Q2 FY25	Q/Q Change
Revenue	$85.2M	↑ 107.18%
Net Income	$23.6M	↓ 163.12%
Net Profit Margin	27.69%	↑ 118.56%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$404.5M	↑ 28.88%

	FY20	Y/Y Change
Profit	$298.3M	↓ 26.26%

	FY21	Y/Y Change
Profit	$412.2M	↑ 38.18%

	FY22	Y/Y Change
Profit	$409.2M	↓ 0.74%

	FY23	Y/Y Change
Profit	$442.7M	↑ 8.2%

	FY24	Y/Y Change
Profit	$343.9M	↓ 22.33%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$74.4M	↓ 36.46%

	Q2 FY24	Q/Q Change
Profit	$93.9M	↑ 26.26%

	Q3 FY24	Q/Q Change
Profit	$61.8M	↓ 34.22%

	Q4 FY24	Q/Q Change
Profit	$90.5M	↑ 46.6%

	Q1 FY25	Q/Q Change
Profit	$40.7M	↓ 55.09%

	Q2 FY25	Q/Q Change
Profit	$84.8M	↑ 108.47%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$10.7M	↓ 115.13%
Investing Cash Flow	$-11.1M	↓ 112.54%
Financing Cash Flow	$-1.2M	↓ 103.94%

	FY20	Y/Y Change
Operating Cash Flow	$168.8M	↑ 1474.23%
Investing Cash Flow	$-1.8M	↓ 83.47%
Financing Cash Flow	$18.5M	↓ 1665.06%

	FY21	Y/Y Change
Operating Cash Flow	$261.9M	↑ 55.12%
Investing Cash Flow	$-265.0K	↓ 85.61%
Financing Cash Flow	$-4.6M	↓ 124.53%

	FY22	Y/Y Change
Operating Cash Flow	$273.8M	↑ 4.53%
Investing Cash Flow	$-136.0K	↓ 48.68%
Financing Cash Flow	$-237.6M	↑ 5120.95%

	FY23	Y/Y Change
Operating Cash Flow	$183.4M	↓ 33.0%
Investing Cash Flow	$-1.0B	↑ 754545.59%
Financing Cash Flow	$277.2M	↓ 216.67%

	FY24	Y/Y Change
Operating Cash Flow	$103.5M	↓ 43.55%
Investing Cash Flow	$-142.0K	↓ 99.99%
Financing Cash Flow	$-107.0M	↓ 138.6%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$45.0M	↑ 25.54%
Investing Cash Flow	$-68.0K	↓ 98.38%
Financing Cash Flow	$-15.6M	↓ 69.44%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$33.5M	↓ 25.61%
Investing Cash Flow	$-58.0K	↓ 14.71%
Financing Cash Flow	$-49.4M	↑ 217.4%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$9.9M	↓ 70.46%
Investing Cash Flow	$-16.0K	↓ 72.41%
Financing Cash Flow	$-27.2M	↓ 45.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$15.2M	↑ 53.91%
Investing Cash Flow	$-16.0K	↑ 0.0%
Financing Cash Flow	$-14.9M	↓ 45.18%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$20.0M	↑ 31.16%
Investing Cash Flow	$-31.0K	↑ 93.75%
Financing Cash Flow	$6.0K	↓ 100.04%

Ironwood Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Ironwood Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Ironwood Pharmaceuticals, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ironwood Pharmaceuticals, Inc.	73.43%	-12.83%	-73.39%	-87.77%	-86.45%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ironwood Pharmaceuticals, Inc.	92.77	NA	-0.26	0.21	-5.75	0.16	NA	-1.9
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ironwood Pharmaceuticals, Inc.	Buy	$214.4M	-86.45%	92.77	-2.56%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Organization	Ironwood Pharmaceuticals
Employees	253
CEO	Mr. Thomas A. McCourt
Industry	Health Technology

Key Management of Ironwood Pharmaceuticals, Inc.

Name	Title
Mr. Thomas A. McCourt	CEO & Director
Mr. John Minardo	Senior VP, Chief Legal Officer & Secretary
Dr. Michael Shetzline M.D., Ph.D.	Chief Medical Officer, Senior VP and Head of Research & Drug Development
Mr. Gregory Martini	Senior VP, CFO & Investor Relations
Mr. Ronald Silver	Senior VP, Corporate Controller & Principal Accounting Officer
Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.	VP & Global Head of Technical Operations

Important FAQs about investing in IRWD Stock from India :

What is Ironwood Pharmaceuticals share price today?

Ironwood Pharmaceuticals share price today is $1.32 as on August 30, 2025 at 1:29 am IST at the close of the market. Ironwood Pharmaceuticals share today touched a day high of $1.33 and a low of $1.30.

What is the 52 week high and 52 week low for Ironwood Pharmaceuticals share?

Ironwood Pharmaceuticals share touched a 52 week high of $5.19 and a 52 week low of $0.53. Ironwood Pharmaceuticals stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $1.32, lower by 74.57% versus the 52 week high.

How to invest in Ironwood Pharmaceuticals Stock (IRWD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Ironwood Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ironwood Pharmaceuticals Shares that will get you 1.1364 shares as per Ironwood Pharmaceuticals share price of $1.32 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Ironwood Pharmaceuticals Stock (IRWD) from India?

Indian investors can start investing in Ironwood Pharmaceuticals (IRWD) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Ironwood Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Ironwood Pharmaceuticals share’s latest price of $1.32 as on August 30, 2025 at 1:29 am IST, you will get 7.5758 shares of Ironwood Pharmaceuticals. Learn more about fractional shares .

What are the returns that Ironwood Pharmaceuticals has given to Indian investors in the last 5 years?

Ironwood Pharmaceuticals stock has given -86.45% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?